Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis.

Oncol Res · 2025 · PMC12408859 · PMID 40918455

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

approaching borderline significanceno p-value reported

4.2 months; p = 0.094), approaching borderline significance.

also in 28 other papers

a notable trendno p-value reported

Furthermore, we observed a notable trend in the limited subset of patients receiving RC48 in combination with chemotherapy.

also in 2,380 other papers

did not reach statistical significanceno p-value reported

In contrast, other evaluated variables, including age, family tumor history, and metastatic site distribution, did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.